Johnson & Johnson JNJ Chief Executive

What Joaquin Duato says in public, and what their own SEC filings show they own.

Joaquin Duato

Joaquin Duato

Chairman & Chief Executive Officer · Johnson & Johnson

CEO since January 2022, Chairman since January 2023. Leads ~138,000 employees globally, directing an R&D portfolio of nearly $17B annually across pharmaceuticals and MedTech.

Leadership & board →
What they own

Ownership

Skin in the game
1/ 70
Level 1Steward

Duato owns about 0% of Johnson & Johnson, worth $81.5M at the last close.

SEC filings
42
Stake 307,837 reported shares ≈ 0.0% of shares outstanding — no 13G on file, so an estimate 4/35
Founder Not assessed — whether they founded the company has not been researched Not assessed
Tenure No start date on record, so tenure scores nothing 0/10
Track record Not assessed — their prior companies have not been researched Not assessed
Direction Sold 271,771 shares ($66.8M) — more than a tenth of the stake — in the last year -10/15
Discipline 2 late Form 4s in 42 filings 7/10

Nobody has researched this person's career yet, so founder and track record are left out of the score and of the total above.

Score = stake band (35) + founder (15) + tenure (10) + track record (15) + 12-month direction (−10…15) + filing discipline (10). An axis we have not researched is left out of the score and of the total it is shown over. Every input links to a filing or to our own research; the bands are ours.

Reported · Forms 3, 4, 5 307,837 Every lot on the person's own filings, as of Aug 13, 2026
Last open-market trade Sale · $32.2M Aug 13, 2026 · 123,291 shares at $261.17 avg · no 10b5-1 plan
Paper trail 2 late filings Form 4 covering a 2022-02-14 grant or award in JOHNSON & JOHNSON was filed 2022-02-17, 3 business days later; Section 16 allows two.
Reported Johnson & Johnson shares Forms 3, 4 and 5 · as of 2026-08-13
0200K400K600K 20162017201820192020202120222023202420252026 Aug 2026: net −48,460 shares across 3 movements (largest: exercise +123,291)Feb 2026: net +48,490 shares across 4 movements (largest: exercise +76,523)Jan 2026: net −99,986 shares across 1 movement (largest: sale −100,000) 307,837

Dots mark the months the activity below moved the line. Hover one for that month's net move, how many movements it folds and the largest.

How the stake is held
SecurityHeld viaShares
Common StockDirect275,967
Common Stockspouse30,852
Common Stock401k1,018
Reported as of 2026-08-13307,837
Held directly
90%
Vehicles
2 trusts or entities
Last filing
Aug 14, 2026
Activity · last 12 months 8 events folded from 15 filing lines · Every filing on EDGAR ↗
DateTypeWhat happenedSharesPriceValueNote
Aug 13, 2026 Exercise Option or RSU conversion +123,291 $115.67 $14.3M
Aug 13, 2026 Sale Open-market sale across 2 lots, $261.00–$262.00 −123,291 $261.17 avg $32.2M no 10b5-1 plan
Aug 5, 2026 Sale Open-market sale across 2 lots, $258.06–$258.74 −48,480 $258.15 avg $12.5M no 10b5-1 plan
Feb 15, 2026 Exercise Option or RSU conversion across 2 lots +8,187 — —
Feb 15, 2026 Tax Shares withheld for tax across 2 lots −3,562 $243.45 $867K
Feb 13, 2026 Exercise Option or RSU conversion across 2 lots +76,523 — —
Feb 13, 2026 Tax Shares withheld for tax across 2 lots −32,668 $244.55 $8.0M
Jan 26, 2026 Sale Open-market sale across 2 lots, $220.99–$221.48 −100,000 $221.23 avg $22.1M Through spouse · no 10b5-1 plan
Every issuer Joaquin Duato files as an insider of
CompanyRoleReportedBeneficial% of class
JNJ JOHNSON & JOHNSON This page CEO and Chairman of the Board 307,837
2026-08-13		 — —
HES HESS CORP Director 6,392
2021-03-06		 — —

Reported is every lot on the person's own Forms 3, 4 and 5 — direct and through trusts. Beneficial is the figure stated on the latest Schedule 13D/G cover page, which can exclude shares the person disclaims and include options exercisable within 60 days, so the two are never added together.

Paper trail

42 filings under CIK 0001673401 · captured 2026-09-05 · All filings on EDGAR ↗

On the record with shareholders

Earnings calls

  1. Q2 2026 Jul 15, 2026 Duato's argument was that Johnson & Johnson has already stopped being a STELARA story. He led on the quarter's beat and the raised guidance, then anchored the year on a single number — sales above $25 billion put the company on track for its first $100 billion year in a 140-year history — and framed the base under it as 28 separate platforms each above $1 billion in annual sales, no one of which the company depends on. That framing did the work when the call turned to the quarter's visible weak spot: heart recovery, where a neutral UK trial slowed Impella use, was placed as one of those 28 and declared temporary, fully addressable and irrelevant to the growth trajectory. What he asked investors to carry away was not the second quarter but the shape of the decade — a stronger second half, momentum into 2027, and double-digit growth by 2030, which he called one of the most compelling and transparent growth stories in health care. Read the call · 4 quotes →
In their own words

Podcasts, interviews & articles

5 recorded appearances

2026

2025

Who else runs a company like this one

Every CEO we track →
Andrew Dudum Hims & Hers Health, Inc. (HIMS) David A. Ricks David A. Ricks Eli Lilly and Company (LLY) Robert A. Michael AbbVie Inc. (ABBV) Stephen J. Hemsley Stephen J. Hemsley UnitedHealth Group Incorporated (UNH)